OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC) WALTHAM, Mass., Feb 03, 2006 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) -- Combretastatin A4P (CA4P) will be Evaluated with

OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213) WALTHAM, Mass., Sep 12, 2006 (BUSINESS WIRE) -- OXiGENE, Inc.

CORRECTION: OXiGENE Participates in 4th Annual International Conference on Antiangiogenesis WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 11, 2006--This replaces the announcement made at 14:00 ET on October 10, 2006 due to the following correction: first graph, second sentence of release should read: Dr.

David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors WALTHAM, Mass., Dec 01, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): -- Dr.

Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2005--OXiGENE, Inc.

Combined Experience Includes Integral Involvement in Development of Multiple Blockbuster Oncology Products, Including Erbitux(r), Tarceva(r) and Taxol(r)

First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 8, 2006--OXiGENE, Inc.

Triple-drug combination therapy shows promising antineoplastic activity

SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the special meeting of stockholders scheduled for

SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc . (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced a collaboration under which sites affiliated with US